Compare Northrop Grumman Corporation (NOC) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Northrop Grumman Corporation vs Pfizer Inc — how do they compare? Northrop Grumman Corporation trades at $479.73 (market cap $68.83B), while Pfizer Inc trades at $28.16 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 2.3× Northrop Grumman Corporation's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Northrop Grumman Corporation for 81 Days and Pfizer Inc for 158 Days on average.
| NOC | PFE | |
|---|---|---|
Market Cap | $68.83B | $158.56B |
Volume | 1,081,989 | 44,138,282 |
Sector | Industrials | Health |
52-Week High | $768.02 | $29.02 |
52-Week Low | $473.46 | $23.67 |
Typical Hold Time | 81 Days | 158 Days |
Enterprise Value | $82.81B | $210.06B |
Dividend Yield | 2.04% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Northrop Grumman (NOC) trades at $480.85, up 1.56% with recent earnings beats but faces technical bearish signals. The company maintains strong fundamentals with $41.95B revenue, 10.48% net margin, and attractive valuation at 15.4 P/E. Recent news highlights both contract wins and competitive losses, including Boeing's $20B Navy fighter award.
Outlook remains positive with analyst consensus at $600.62 target (25% upside) and 54% buy ratings. Key risks include defense contract volatility and competitive pressures, while strong backlog ($104.7B) and dividend growth support long-term value. The stock offers defensive exposure to elevated defense spending cycles.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
